Nexalin Technology plans pivotal trial for insomnia device
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
April 22, 2026 9:35 AM EDT160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia
HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the Company or Nexalin), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the brain, today announced it has entered into agreements to advance its planned pivotal clinical trial evaluating the HALO Clarity device for the treatment of moderate-to-severe insomnia, with patient enrollment currently expected to begin in Q2 of 2026.
The 160-participant, randomized, triple-blinded, sham-controlled clinical trial is intended to support Nexalins... More
